Pediatric Drugs

, Volume 14, Issue 4, pp 271–279

Live Attenuated Influenza Vaccine (Fluenz™)

A Guide to its Use in the Prevention of Seasonal Influenza in Children in the EU
  • Lesley J. Scott
  • Natalie J. Carter
  • Monique P. Curran
Adis Drug Clinical Q&A

DOI: 10.2165/11207080-000000000-00000

Cite this article as:
Scott, L.J., Carter, N.J. & Curran, M.P. Pediatr Drugs (2012) 14: 271. doi:10.2165/11207080-000000000-00000

Abstract

Live attenuated influenza vaccine (LAIV) [Fluenz™] has a convenient intranasal route of administration. In the EU, it is indicated for the prevention of influenza disease caused by the influenza virus strains contained in the vaccine in children and adolescents aged 2 years to <18 years. The vaccine elicits a high immunogenic response, is protective against seasonal influenza infection and is associated with the development of herd immunity. LAIV is generally well tolerated, with the safety of the vaccine in the approved pediatric population generally considered to be similar to that of placebo based on clinical trials and extensive experience involving more than 39 million vaccine doses.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • Natalie J. Carter
    • 1
  • Monique P. Curran
    • 1
  1. 1.AdisAucklandNew Zealand